Nucleic Acid Testing (NAT) Market by Product, consumables, ligase chain reaction and whole genome sequencing), by Application, by End-User, and Regions — Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2019–2026

The Global Nucleic Acid Testing (NAT) Market is valued to reach USD 4.8 Billion by 2025, growing at CAGR of 9.5% during forecast period 2020–2026. Increasing prevalence of infectious and genetic diseases, growing adoption of blood screening methods and advances in gene editing technologies are augmenting the market growth.

Get Sample Report: https://dataintelo.com/request-sample/?reportId=83542

Nucleic Acid Testing (NAT) involves the infectiousness of hepatitis C virus and HIV in the blood supply. The technique involves molecular methods for screening blood samples to lessen the risk of transmitted diseases. Nucleic Acid Testing (NAT) is a technique that is highly specific and sensitive for viral nucleic acids and is based on amplification of viral ribonucleic acid or deoxyribonucleic acids that detects them other than screening methods. The Food and Drug Administration has strengthened the regulations for blood transfusion and protects the patients from encountering contaminated blood and blood products. In fact, FDA empowers blood donors to enquire for blood exchange. Moreover, in the past years, the blood establishments have imparted new screening tests comprising sensitive tests, nucleic acid tests which has resulted in reduction of HIV-1 transmission.

Nucleic Acid Testing (NAT) Market Trends, Drivers and Opportunities:

Nucleic Acid Testing (NAT) market is driven by increase in demand and technological progress in the healthcare industry. In addition, the demand for enhanced methods such as preparation testing, amplification and sample extraction is anticipated to trigger the market growth by leap and bounds. Additionally, detection of pathogens in blood samples is a significant factors that boosts the market. Rise in chronic health conditions arising out of genetic mutations and prolonged diseases is likely to demand testing methodologies in the years to come. In addition, healthcare conditions is a major driving factor in the following years. However, the lack of awareness and dearth of medical competence followed by delayed response to epidemic outbreak confines the market growth.